Table 1 Demographic and clinical characteristics of cohorts 1 and 2. GR and NR indicate EULAR good responders and non-responders respectively. Numbers in brackets after each attribute represent percentages or standard deviation (SD) of that attribute, as indicated

N

19

21

N/A

21

15

N/A

Female, N (%)

15 (79)

19 (90)

0.56

16 (76)

12 (80)

1

Age^§, mean (SD)

54 (13)

56 (13)

0.48

55 (12)

51 (9.9)

0.41

White, N (%)

17 (89)

14 (67)

0.18

19 (90)

13 (87)

1

BMI^§, mean (SD)

29 (7.6)

30 (6.3)

0.45

30 (7)

33 (7.1)

0.092

College educated^§, N (%)

10 (53)

13 (62)

0.79

12 (57)

10 (67)

0.82

Non-smoker^§, N (%)

8 (42)

14 (67)

0.21

14 (67)

9 (60)

0.95

Current or previous smoker^§, N (%)

11 (58)

7 (33)

0.21

7 (33)

6 (40)

0.95

Infliximab, N (%)

8 (42)

9 (43)

1

6 (29)

8 (53)

0.25

Adalimumab, N (%)

11 (58)

12 (57)

1

15 (71)

7 (47)

0.25

SJC28 [BL]^§, mean (SD)

6.7 (3.7)

9.1 (5.5)

0.18

9.6 (5.5)

8.7 (4.9)

0.75

TJC28 [BL], mean (SD)*

9 (6.2)

15 (8.3)

0.027

11 (6.7)

14 (5.7)

0.16

ln (CRP) [BL]^§, mean (SD)

1.6 (1.6)

1.2 (1.8)

0.53

1.5 (1.4)

1.8 (1.1)

0.43

DAS28-CRP [BL], mean (SD)*

4.5 (0.78)

5.2 (0.94)

0.016

4.8 (0.83)

5.2 (0.66)

0.054

RA duration^§, mean (SD)*

5.4 (7.5)

1.9 (1.7)

0.023

5 (6.5)

7.2 (8.3)

0.5

RF+, N (%)

16 (84)

12 (57)

0.13

16 (76)

8 (53)

0.28

CCP+, N (%)*

16 (84)

8 (38)

0.0081

17 (81)

6 (40)

0.03